LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 189

Search options

  1. Book: Therapieoptionen bei schwerem Asthma

    Idzko, Marco

    leitliniengerechte Therapie im Fokus

    (Therapie Report spezial ; 6. Jahrgang, Heft 2 (Juni 2018))

    2018  

    Author's details Herausgeber Univ. Prof. Dr. Marco Idzko
    Series title Therapie Report spezial ; 6. Jahrgang, Heft 2 (Juni 2018)
    Therapie Report Spezial
    Collection Therapie Report Spezial
    Language German
    Size 11 Seiten
    Publisher Thieme
    Publishing place Stuttgart
    Publishing country Germany
    Document type Book
    HBZ-ID HT019760280
    Database Catalogue ZB MED Medicine, Health

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Shelf markLoan statusLocation
    Zs A 7165 -6,2- verfügbar in Königswinter Königswinter

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Inhaled budesonide for early treatment of COVID-19.

    Zeitlinger, Markus / Idzko, Marco

    The Lancet. Respiratory medicine

    2021  Volume 9, Issue 7, Page(s) e59

    MeSH term(s) Administration, Inhalation ; Bronchodilator Agents/therapeutic use ; Budesonide ; COVID-19 ; Humans ; SARS-CoV-2
    Chemical Substances Bronchodilator Agents ; Budesonide (51333-22-3)
    Language English
    Publishing date 2021-05-12
    Publishing country England
    Document type Letter ; Comment
    ZDB-ID 2686754-0
    ISSN 2213-2619 ; 2213-2600
    ISSN (online) 2213-2619
    ISSN 2213-2600
    DOI 10.1016/S2213-2600(21)00215-0
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 7041: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article: Präzisionsmedizin trifft Pneumologie. Interview Univ.-prof. Dr. Marco Idzko

    Idzko, Marco

    Arzt & Praxis

    2018  Volume 72, Issue 5, Page(s) 6

    Language German
    Document type Article
    ZDB-ID 1224197-0
    ISSN 0048-5128
    Database Current Contents Medicine

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 868: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Blocking P2X purinoceptor 4 signalling alleviates cigarette smoke induced pulmonary inflammation.

    Schneider, Sven / Merfort, Irmgard / Idzko, Marco / Zech, Andreas

    Respiratory research

    2022  Volume 23, Issue 1, Page(s) 148

    Abstract: Background: Chronic obstructive pulmonary disease (COPD) is associated with elevated ATP levels in the extracellular space. Once released, ATP serves as danger signal modulating immune responses by activating purinergic receptors. Accordingly, ... ...

    Abstract Background: Chronic obstructive pulmonary disease (COPD) is associated with elevated ATP levels in the extracellular space. Once released, ATP serves as danger signal modulating immune responses by activating purinergic receptors. Accordingly, purinergic signalling has been implicated in respiratory inflammation associated with cigarette smoke exposure. However, the role of P2X4-signalling has not been fully elucidated yet.
    Methods: Here, we analysed the P2X4 mRNA expression in COPD patients as well as cigarette smoke-exposed mice. Furthermore, P2X4-signalling was blocked by either using a specific antagonist or genetic depletion of P2rx4 in mice applied to an acute and prolonged model of cigarette smoke exposure. Finally, we inhibited P2X4-signalling in macrophages derived from THP-1 before stimulation with cigarette smoke extract.
    Results: COPD patients exhibited an increased P2X4 mRNA expression in cells isolated from the bronchoalveolar lavage fluid and peripheral mononuclear cells. Similarly, P2rx4 expression was elevated in lung tissue of mice exposed to cigarette smoke. Blocking P2X4-signalling in mice alleviated cigarette smoke induced airway inflammation as well as lung parenchyma destruction. Additionally, human macrophages derived from THP-1 cells released reduced concentrations of proinflammatory cytokines in response to cigarette smoke extract stimulation when P2X4 was inhibited.
    Conclusion: Taken together, we provide evidence that P2X4-signalling promotes innate immunity in the immunopathologic responses induced by cigarette smoke exposure.
    MeSH term(s) Adenosine Triphosphate/metabolism ; Animals ; Bronchoalveolar Lavage Fluid ; Cigarette Smoking/adverse effects ; Humans ; Immunity, Innate ; Inflammation/metabolism ; Lung/metabolism ; Mice ; Mice, Inbred C57BL ; Pneumonia/chemically induced ; Pneumonia/genetics ; Pneumonia/prevention & control ; Pulmonary Disease, Chronic Obstructive/metabolism ; Purinergic P2X Receptor Antagonists/pharmacology ; RNA, Messenger/genetics ; RNA, Messenger/metabolism ; Receptors, Purinergic P2X4/genetics ; THP-1 Cells
    Chemical Substances Purinergic P2X Receptor Antagonists ; RNA, Messenger ; Receptors, Purinergic P2X4 ; Adenosine Triphosphate (8L70Q75FXE)
    Language English
    Publishing date 2022-06-08
    Publishing country England
    Document type Journal Article
    ZDB-ID 2041675-1
    ISSN 1465-993X ; 1465-993X
    ISSN (online) 1465-993X
    ISSN 1465-993X
    DOI 10.1186/s12931-022-02072-z
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: Angioedema as a predominant symptom of

    Bal, Christina / Baumgartner, Ruth / Gompelmann, Daniela / Idzko, Marco

    BMJ case reports

    2021  Volume 14, Issue 3

    Abstract: A 41-year-old woman was referred to our hospital with a 6-week history of severe angioedema, dyspnoea and coughing. Initial investigations focused on common causes of angioedema. Clinical presentation and resistance to treatment with antihistamines and ... ...

    Abstract A 41-year-old woman was referred to our hospital with a 6-week history of severe angioedema, dyspnoea and coughing. Initial investigations focused on common causes of angioedema. Clinical presentation and resistance to treatment with antihistamines and steroids made histamine-mediated angioedema unlikely. Bradykinin-mediated angioedema, such as hereditary or drug-induced angioedema, was excluded by a thorough history investigation and laboratory testing for C1-esterase and C4.In rare cases, exogen pathogens cause angioedema. After profound testing for respiratory pathogens,
    MeSH term(s) Adult ; Angioedema/diagnosis ; Angioedema/etiology ; Antibodies, Bacterial ; Bordetella pertussis ; Bradykinin ; Female ; Humans ; Whooping Cough/complications ; Whooping Cough/diagnosis ; Whooping Cough/drug therapy
    Chemical Substances Antibodies, Bacterial ; Bradykinin (S8TIM42R2W)
    Language English
    Publishing date 2021-03-02
    Publishing country England
    Document type Case Reports ; Journal Article
    ISSN 1757-790X
    ISSN (online) 1757-790X
    DOI 10.1136/bcr-2020-239243
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  6. Article: Asthma und Long COVID. Der Einsatz oraler Kortikosteroide sollte bei schwerem Asthma auf ein Minimum reduziert werden. 2 DFP-Punkte

    Idzko, Marco / Pohl, Wolfgang / Koczulla, Rembert

    Arzt & Praxis

    2022  Volume 76, Issue 4, Page(s) 10

    Language German
    Document type Article
    ZDB-ID 1224197-0
    ISSN 0048-5128
    Database Current Contents Medicine

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 868: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article ; Online: Dupilumab rapidly improves asthma control in predominantly anti-IL5/IL5R pretreated Austrian real-life severe asthmatics.

    Renner, Andreas / Marth, Katharina / Patocka, Karin / Idzko, Marco / Pohl, Wolfgang

    Immunity, inflammation and disease

    2021  Volume 9, Issue 3, Page(s) 624–627

    Abstract: Dupilumab is a monoclonal antibody against the IL-4 receptor alpha which has shown efficacy in T2 high severe asthmatics in phase 3 randomized controlled trials. The purpose of this real-life study is to demonstrate the real-life effectiveness of ... ...

    Abstract Dupilumab is a monoclonal antibody against the IL-4 receptor alpha which has shown efficacy in T2 high severe asthmatics in phase 3 randomized controlled trials. The purpose of this real-life study is to demonstrate the real-life effectiveness of dupilumab in Austrian severe asthma patients. We retrospectively analyzed all patients receiving dupilumab at our severe asthma clinic. Thirteen patients have so far received dupilumab at our center. The primary outcome, asthma control questionnaire 6-item scale at 2 weeks, improved by 0.57 points (p = .014), which is statistically and clinically significant. Similarly, the asthma control test at 4 weeks improved by 3.91 points (p = .024), also statistically and clinically significant. Improvements in forced expiratory volume in 1 s at 2 weeks were neither statistically, nor clinically significant. Improvements at 4 weeks (+220 ml, p = .041), and 3 months (+229 ml, p = .006), were statistically significant and clinically borderline significant. No severe adverse events or hypereosinophilia were observed. No adverse events led to treatment discontinuation. Most patients (85%) had previously received monoclonal antibody treatment for severe asthma. Previous monoclonal antibody treatment had been discontinued in these patients due to a lack of clinical response. Dupilumab is effective and safe in Austrian real-life severe asthmatics. It provides a possible treatment strategy for T2 high severe asthmatics who do not qualify for anti-immunoglobulin E or anti-IL5/IL5R monoclonal antibody treatments or do not adequately respond to these.
    MeSH term(s) Antibodies, Monoclonal, Humanized ; Asthma/drug therapy ; Austria ; Humans ; Retrospective Studies
    Chemical Substances Antibodies, Monoclonal, Humanized ; dupilumab (420K487FSG)
    Language English
    Publishing date 2021-05-07
    Publishing country England
    Document type Journal Article
    ISSN 2050-4527
    ISSN (online) 2050-4527
    DOI 10.1002/iid3.434
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  8. Article: SARS-CoV-2 Infection and Active, Multiorgan, Severe cGVHD After HSCT for Adolescent ALL: More Luck Than Understanding? A Case Report.

    Zubarovskaya, Natalia / Hofer-Popow, Irene / Idzko, Marco / Haas, Oskar A / Lawitschka, Anita

    Frontiers in pediatrics

    2022  Volume 9, Page(s) 775318

    Abstract: Graft-vs. -host disease (GvHD) is a serious and complex immunological complication of haematopoietic stem cell transplantation (HSCT) and is associated with prolonged immunodeficiency and non-relapse mortality. Standard treatment of chronic GvHD ... ...

    Abstract Graft-vs. -host disease (GvHD) is a serious and complex immunological complication of haematopoietic stem cell transplantation (HSCT) and is associated with prolonged immunodeficiency and non-relapse mortality. Standard treatment of chronic GvHD comprises steroids in combination with other immunosuppressive agents. Extracorporeal photopheresis (ECP), with its immunomodulatory mechanism, is applied as part of steroid-sparing regimens for chronic GvHD. Immunocompromised, chronically ill patients are at particular risk of severe disease courses of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. T-cell immunity in SARS-CoV-2 infection is well-described but the role of the humoral immune responses is not fully understood. This case report describes a moderate course of SARS-CoV-2 infection in a patient <9 months after HSCT who was suffering from active, severe, chronic GvHD treated with prednisone and ECP. Following HSCT from a matched unrelated donor to cure acute lymphoblastic leukaemia, the 25-year-old male patient experienced multiple infectious complications associated with cytopenia, B-cell dyshomeostasis and autoantibody production followed by development of severe chronic GvHD thereafter at day +212. The steroid-sparing treatment plan consisted of supportive care, topical treatment, prednisone and ECP. He was diagnosed with SARS-CoV-2 infection at day +252, experiencing loss of smell and taste as well as a cough. The patient's oxygen saturation was between 94 and 97% on room air, and computed tomography images showed evolution of typical of SARS-CoV-2 infiltrates. In addition to cytopenia and immune dyshomeostasis, laboratory tests confirmed macrophage activating syndrome, transaminitis and Epstein-Barr virus viraemia. At that time, anti-SARS-CoV-2 monoclonal antibodies were not available in Austria and remdesivir seemed contraindicated. Surprisingly, despite severe lymphopenia the patient developed SARS-CoV-2-specific antibodies within 15 days, which was followed by clearance of SARS-CoV-2 and EBV with resolution of symptoms. Thereafter, parameters of immune dysregulation such as lymphopenia and B-cell dyshomeostasis, the latter characterised by elevated CD21
    Language English
    Publishing date 2022-01-14
    Publishing country Switzerland
    Document type Case Reports
    ZDB-ID 2711999-3
    ISSN 2296-2360
    ISSN 2296-2360
    DOI 10.3389/fped.2021.775318
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article: Sustained Treatment Response after Intravenous Cyclophosphamide in a Patient with Therapy-Resistant COVID-19 Acute Respiratory Distress Syndrome: A Case Report.

    Haselwanter, Patrick / Bal, Christina / Gompelmann, Daniela / Idzko, Marco / Prosch, Helmut / Zauner, Christian / Schneeweiss-Gleixner, Mathias

    Journal of clinical medicine

    2023  Volume 12, Issue 17

    Abstract: Treatment of acute respiratory distress syndrome (ARDS) represents a severe complication of coronavirus disease 2019 (COVID-19) infection and is often challenging in intensive care treatment. Potential positive effects of intravenous cyclophosphamide ... ...

    Abstract Treatment of acute respiratory distress syndrome (ARDS) represents a severe complication of coronavirus disease 2019 (COVID-19) infection and is often challenging in intensive care treatment. Potential positive effects of intravenous cyclophosphamide have been reported in interstitial lung diseases (ILDs). However, there are no data on the use of high-dose cyclophosphamide in therapy-resistant COVID-19 ARDS. We report the case of a 32-year-old male patient admitted to the intensive care unit (ICU) of the Medical University of Vienna due to severe COVID-19 ARDS who required venovenous extracorporeal membrane oxygenation (ECMO) with a total runtime of 85 days. Despite all these therapeutic efforts, he remained in a condition of therapy-resistant ARDS. Unfortunately, the patient was denied for lung transplantation. However, a significant improvement in his respiratory condition was achieved after the administration of an intravenous regimen of cyclophosphamide and prednisolone. After a period of consecutive stabilization, the patient was transferred to the normal ward after 125 days of intensive care treatment. There is a substantial lack of therapeutic options in therapy-resistant ARDS. Our case report suggests that cyclophosphamide may represent a new treatment strategy in therapy-resistant ARDS. Due to its severe adverse effect profile, cyclophosphamide should be used after careful evaluation of a patient's general condition.
    Language English
    Publishing date 2023-08-24
    Publishing country Switzerland
    Document type Case Reports
    ZDB-ID 2662592-1
    ISSN 2077-0383
    ISSN 2077-0383
    DOI 10.3390/jcm12175506
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article ; Online: Cell-type-specific role of P2Y2 receptor in HDM-driven model of allergic airway inflammation.

    Schneble, Dominik / El-Gazzar, Ahmed / Kargarpour, Zahra / Kramer, Markus / Metekol, Seda / Stoshikj, Slagjana / Idzko, Marco

    Frontiers in immunology

    2023  Volume 14, Page(s) 1209097

    Abstract: Allergic airway inflammation (AAI) is a chronic respiratory disease that is considered a severe restriction in daily life and is accompanied by a constant risk of acute aggravation. It is characterized by IgE-dependent activation of mast cells, ... ...

    Abstract Allergic airway inflammation (AAI) is a chronic respiratory disease that is considered a severe restriction in daily life and is accompanied by a constant risk of acute aggravation. It is characterized by IgE-dependent activation of mast cells, infiltration of eosinophils, and activated T-helper cell type 2 (Th2) lymphocytes into airway mucosa. Purinergic receptor signaling is known to play a crucial role in inducing and maintaining allergic airway inflammation. Previous studies in an ovalbumin (OVA)-alum mouse model demonstrated a contribution of the P2Y2 purinergic receptor subtype (P2RY2) in allergic airway inflammation. However, conflicting data concerning the mechanism by which P2RY2 triggers AAI has been reported. Thus, we aimed at elucidating the cell-type-specific role of P2RY2 signaling in house dust mite (HDM)-driven model of allergic airway inflammation. Thereupon, HDM-driven AAI was induced in conditional knockout mice, deficient or intact for
    MeSH term(s) Mice ; Animals ; Receptors, Purinergic P2Y2/genetics ; Receptors, Purinergic P2Y2/metabolism ; Cytokines/metabolism ; Lung/pathology ; Pyroglyphidae ; Inflammation/metabolism
    Chemical Substances Receptors, Purinergic P2Y2 ; Cytokines
    Language English
    Publishing date 2023-09-14
    Publishing country Switzerland
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2606827-8
    ISSN 1664-3224 ; 1664-3224
    ISSN (online) 1664-3224
    ISSN 1664-3224
    DOI 10.3389/fimmu.2023.1209097
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top